SR 141716A
SR 141716A structure
|
Common Name | SR 141716A | ||
|---|---|---|---|---|
| CAS Number | 158681-13-1 | Molecular Weight | 500.248 | |
| Density | N/A | Boiling Point | 627.6ºC at 760 mmHg | |
| Molecular Formula | C22H22Cl4N4O | Melting Point | 230-240ºC | |
| MSDS | Chinese USA | Flash Point | 333.3ºC | |
| Symbol |
GHS06 |
Signal Word | Danger | |
|
Obesity drug therapy.
Minerva Endocrinol. 38(3) , 245-54, (2013) Obesity is a chronic disease, and it requires chronic therapy. Hypertension, dyslipidemia, diabetes and cardiovascular diseases are leading causes of mortality in the modern world. All of them are strongly linked to obesity. While treating obesity, those cond... |
|
|
Anandamide-CB1 receptor signaling contributes to postnatal ethanol-induced neonatal neurodegeneration, adult synaptic, and memory deficits.
J. Neurosci. 33(15) , 6350-66, (2013) The transient exposure of immature rodents to ethanol during postnatal day 7 (P7), which is comparable with the third trimester in human pregnancy, induces synaptic dysfunctions. However, the molecular mechanisms underlying these dysfunctions are still poorly... |
|
|
Reduced food intake is the major contributor to the protective effect of rimonabant on islet in established obesity-associated type 2 diabetes.
Yonsei Med. J. 54(5) , 1127-36, (2013) Although the presence of cannabinoid type 1 (CB1) receptor in islets has been reported, the major contributor to the protective effect of rimonabant on islet morphology is unknown. We determined whether the protective effect of rimonabant on pancreatic islet ... |
|
|
Peripherally restricted CB1 receptor blockers.
Bioorg. Med. Chem. Lett. 23(17) , 4751-60, (2013) Antagonists (inverse agonists) of the cannabinoid-1 (CB1) receptor showed promise as new therapies for controlling obesity and related metabolic function/liver disease. These agents, representing diverse chemical series, shared the property of brain penetrati... |
|
|
Rimonabant dimorphism and its pressure-temperature phase diagram: a delicate case of overall monotropic behavior.
J. Pharm. Sci. 102(7) , 2311-21, (2013) Crystalline polymorphism occurs frequently in the solid state of active pharmaceutical ingredients, and this is problematic for the development of a suitable dose form. Rimonabant, an active pharmaceutical ingredient developed by Sanofi and discontinued becau... |
|
|
Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
Am. J. Physiol. Endocrinol. Metab. 306(4) , E457-68, (2014) The adipocyte-derived hormone adiponectin promotes fatty acid oxidation and improves insulin sensitivity and thus plays a key role in the regulation of lipid and glucose metabolism and energy homeostasis. Chronic cannabinoid type 1 (CB1) receptor blockade als... |
|
|
Additive effect of rimonabant and citalopram on extracellular serotonin levels monitored with in vivo microdialysis in rat brain
Eur. J. Pharmacol. 709(1-3) , 13-9, (2013) Current pharmacological therapies for depression, including selective serotonin reuptake inhibitors (SSRI), are far from ideal. The cannabinoid system has been implicated in control of mood and neural processing of emotional information, and the modulation of... |
|
|
Bladder function in a cannabinoid receptor type 1 knockout mouse.
BJU Int. 113(1) , 144-51, (2014) To evaluate bladder function in an established cannabinoid type 1 (CB1) receptor knockout (KO) mouse model via organ-bath (in vitro) and urodynamic (cystometric; in vivo) experiments.In all, 20 8-week-old female wildtype (WT) mice (C57BL/6) and 20 age-matched... |
|
|
Blockade of cannabinoid receptors reduces inflammation, leukocyte accumulation and neovascularization in a model of sponge-induced inflammatory angiogenesis.
Inflamm. Res. 62(8) , 811-21, (2013) Angiogenesis depends on a complex interaction between cellular networks and mediators. The endocannabinoid system and its receptors have been shown to play a role in models of inflammation. Here, we investigated whether blockade of cannabinoid receptors may i... |
|
|
Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.
Naunyn Schmiedebergs Arch. Pharmacol. 386(8) , 721-32, (2013) Effects of cannabinoid receptor 1 (CB1R) blockade were observed by comparing 9-day and 6-week SR141716 treatments in monosodium glutamate (MSG)-induced hypometabolic and hypothalamic obesity (HO) in rats for the first time and molecular mechanisms were invest... |